Rocket Pharmaceuticals, Inc. Common Stock
RCKT Real Time Price USDRecent trades of RCKT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by RCKT's directors and management
Government lobbying spending instances
-
$10,000 Jul 19, 2022 Issue: Health Issues
-
$10,000 Apr 20, 2022 Issue: Health Issues
-
$10,000 Jan 20, 2022 Issue: Health Issues
-
$10,000 Nov 19, 2021 Issue: Health Issues
-
$10,000 Jul 19, 2021 Issue: Health Issues
-
$30,000 Oct 20, 2020 Issue: Immigration
-
$20,000 Jul 17, 2020 Issue: Immigration
-
$20,000 Apr 13, 2020 Issue: Immigration
-
$40,000 Jan 15, 2020 Issue: Immigration
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Gene therapy vectors for treatment of danon disease Jul. 07, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of RCKT in WallStreetBets Daily Discussion
Recent insights relating to RCKT
Recent picks made for RCKT stock on CNBC
ETFs with the largest estimated holdings in RCKT
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RCKT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.